Company Overview and News
Intuitive Surgical is experiencing strong operating momentum and positive consensus estimate momentum, and despite its "high" trading multiple we think the stock has upside potential.
JNJ SYK LGNZZ LGND OR LGNYZ LGNXZ ISRG LGNDZ MDT
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'0O M26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT)R=6EMO
Osisko Gold Royalties Ltd. - SEC Correspondence - Filed by newsfilecorp.com June 6, 2018 Mr. John Reynolds Assistant Director Office of Beverages, Apparel and Mining Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- Strongbow Exploration Inc. (TSX-V:SBW) (“Strongbow” or the “Company”) is pleased to announce the appointment of Ms. Brenda Nowak as Corporate Secretary, commencing with immediate effect.
NHAWF OKSWF SBWFF NAR SWYDF NDR OR KAM KMKGF OSKGF NWDMF SWY CS CSFFF
Here's a monthly recap of the top news in the gold mining sector, including acquisitions and takeover announcements, financial results and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for May, in case you missed it.
AGCBF RIO RIO YRI KGI.DB CG CAGDF RTPPF FPC AUY OR RTNTF FPRGF SEMFF KL WPM SAND SSL SDDXF KGI OKSWF KGI.DB.A SNXZF RGLD AGC RIO OSKGF RGL
Osisko Gold Royalties Ltd. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2018 Commission File Number: 001-
MONTREAL, July 03, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”) announces that it has completed the previously announced purchase from Falco Resources Ltd. (TSXV:FPC) (“Falco”) of a secured debenture having a principal amount of C$7,000,000 (the “Debenture”). The Debenture will, upon approval of the disinterested shareholders of Falco, become convertible (the “Conversion”) into units of Falco, with each unit comprised of one common share of Falco and one-half of one common share purchase warrant of Falco.
FPC OKSWF OR OR OSKGF BGMZF FPRGF
MONTRÉAL, 03 juill. 2018 (GLOBE NEWSWIRE) -- Redevances Aurifères Osisko Ltée (TSX:OR) (NYSE:OR) (« Osisko » ou la « Société ») annonce qu’elle a complété l’acquisition précédemment annoncée d’une débenture garantie de Ressources Falco Ltée (TSX CROISSANCE:FPC) (« Falco ») d’un montant principal de 7 000 000 $ CA (la « débenture »). La débenture sera, suite à l’approbation des actionnaires désintéressés de Falco, convertible (la « conversion ») en unités de Falco, chaque unité comprenant une action ordinaire de Falco et la moitié d’un bon de souscription d’actions ordinaires de Falco.
OR OR BGMZF
MONTREAL, July 03, 2018 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSX-V:FPC) (“Falco” or the “Company”) is pleased to announce that it has closed its previously announced $7 million financing transaction (the “Debenture Financing”) with Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”). Under the terms of the Debenture Financing, Osisko purchased a secured debenture (the “Debenture”) having a principal amount of $7,000,000 (the “Principal”).
FPC OKSWF OR OR OSKGF FPRGF
MONTRÉAL, 03 juill. 2018 (GLOBE NEWSWIRE) -- Ressources Falco Ltée (TSX CROISSANCE:FPC) (« Falco » ou la « Société ») est heureuse d’annoncer qu’elle a clôturé la transaction de financement de 7 millions de dollars précédemment annoncée (le « financement par débenture ») avec Redevances Aurifères Osisko Ltée (TSX:OR) (NYSE:OR) (« Osisko »). En vertu des termes du financement par débenture, Osisko a acquis une débenture garantie (la « débenture ») d’un montant principal de 7 000 000 $ (le « montant principal »).
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) and Orion Mine Finance are pleased to announce that the Company and certain affiliates of Orion Mine Finance (collectively, “Orion”) have entered into a definitive arrangement agreement (the “Arrangement Agreement”), whereby Orion will acquire all of the issued and outstanding common shares of the Company (“Dalradian Shares”) by way of a statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).
DRLDF BLK DNA.WT.A FPC OKSWF DRRLF OR OSKGF FPRGF BGMZF DALR DNA
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET